Checking measles vaccine response in children with sickle cell disease
Verifying Antibodies After Live Immunization Delivery (VALID): a Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease
This study tests whether infants and young children with sickle cell disease develop enough protection in the weeks after their measles vaccine.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 130 (estimated) |
| Ages | 6 Months to 6 Years |
| Sex | All |
| Sponsor | Children's Hospital Medical Center, Cincinnati Academic / other |
| Locations | 3 sites (Cincinnati, Ohio and 2 other locations) |
| Trial ID | NCT07356050 on ClinicalTrials.gov |
What this trial studies
This observational study will enroll children aged 6 months to 6 years with confirmed sickle cell disease who are due for a measles vaccine. Two cohorts will be followed: one receiving the first measles vaccine (MV1) and one receiving the second (MV2). Blood samples will be collected before vaccination and at 4 and 8 weeks after vaccination to measure antibody responses. Sites include Cincinnati Children’s Hospital Medical Center and collaborating hospitals in Ghana and Tanzania.
Who should consider this trial
Good fit: Ideal candidates are children aged 6 months to 6 years with confirmed sickle cell disease who are due for measles vaccination within three months and can attend follow-up visits and provide informed consent through a guardian.
Not a fit: Children with known primary immunodeficiency, cancer, or AIDS who cannot receive live measles vaccine, or children outside the 6-month to 6-year window, are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, the results could show whether standard measles vaccination produces adequate short-term protection in children with sickle cell disease and help guide immunization timing or booster recommendations.
How similar studies have performed: Measuring antibody responses after vaccination is a standard method and has been used in other populations, but data specifically on measles immunogenicity in sickle cell disease are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Participants with confirmed Sickle Cell Disease. 2. Participants 6 months and 6 years of age and due for measles vaccination within 3 months per national guidelines. 3. Willing and able to provide informed consent 4. Ability to comply with study related evaluations and follow-up visits. Exclusion Criteria: 1\. Known primary immunodeficiency syndrome, cancer, or acquired immunodeficiency syndrome (AIDS) that would preclude vaccination with live virus vaccines.
Where this trial is running
Cincinnati, Ohio and 2 other locations
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States (Recruiting)
- Korle Bu Teaching Hospital — Accra, Ghana, Ghana (Recruiting)
- Bugando Medical Centre — Mwanza, Tanzania (Recruiting)
Study contacts
- Principal investigator: Alexandra Power-Hays, MD — Children's Hospital Medical Center, Cincinnati
- Study coordinator: Teresa Latham
- Email: Teresa.Latham@cchmc.org
- Phone: 513-803-7922
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.